UPB — Upstream Bio, Inc.

Is UPB overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Strong Oversold As of November 17, 2026

Upstream Bio, Inc. (UPB) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $2.15. The rating moved from Oversold to Strong Oversold on November 17, 2026.

See all oversold Healthcare stocks →

AI analysis

Upstream Bio, Inc. (UPB) is best characterized as a small, information-sparse biotech whose near-term value depends on clinical/regulatory catalysts and access to financing. The broader market is selectively favoring large-cap pharma and defensive healthcare, which reduces sector flow into smaller, higher-risk biotech names. Absent recent EDGAR filings or clear upcoming milestones, balance between potential upside from positive program news and high dilution/liquidity risk supports a cautious stance. Key risks include financing-driven dilution, trial or regulatory setbacks, and low market liquidity that can magnify price moves.

Key factors

  • Upstream Bio, Inc. (UPB) appears to be a small‑cap biotech with limited publicly available recent filings or social/research coverage, increasing information asymmetry.
  • Biotech business model typically driven by clinical, regulatory and licensing milestones — these are primary near‑term value drivers in absence of commercial revenue.
  • Market environment favoring large‑cap, defensive pharma limits near‑term sector flows to small, higher‑risk biotechs.
  • Sector theme noting convertible‑debt/dilution pressures in diagnostics/biotech raises the probability of financing-related dilution for issuers of this size.
  • Macro risk-on tone may support momentum in growth names, but earnings/catalyst-driven moves dominate and UPB lacks visible, imminent catalysts in public data.

Risks

  • Lack of recent EDGAR filings or transparent financial statements increases execution and liquidity risk.
  • Clinical trial failure or regulatory delay would materially reduce value given likely pipeline dependence.
  • Need for near-term financing could lead to dilutive equity issuance or convertible debt with hedging pressure.
  • Low trading liquidity and limited analyst coverage can amplify volatility and widen bid/ask spreads.
  • Competitive risk from larger pharma/biotech with deeper commercialization and distribution capabilities.
  • General sector derisking favoring large‑cap pharm and defensive flows may reduce investor interest in small biotechs.

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for UPB — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.